Global and United States Eptacog Alfa (rFVIIa) Market Report & Forecast 2022-2028

• Description
• Table of Contents
• Table of Figures
• PDF Download

• Description
• Table of Contents
• Table of Figures
• PDF Download

Recombinant human coagulation factor VIIa is a drug from Novo Nordisk for bleeding episodes and prevention of bleeding during surgical procedures or invasive procedures in the following patient groups:
1. Inhibitors of coagulation factor VIII or IX 5BU in congenital hemophilia patients; 2. Congenital hemophilia patients who are expected to have a high memory response to injection of coagulation factor VIII or coagulation factor IX; 3. Acquired blood 4. Patients with congenital FVII deficiency; 5. Patients with thrombocytopenia who have GP IIb-IIIa and/or HLA antibodies and past or present ineffective or poor platelet transfusions.

Market Analysis and Insights: Global and United States Eptacog Alfa (rFVIIa) Market
This report focuses on global and United States Eptacog Alfa (rFVIIa) market, also covers the segmentation data of other regions in regional level and county level.

Due to the COVID-19 pandemic, the global Eptacog Alfa (rFVIIa) market size is estimated to be worth US$ 1263 million in 2022 and is forecast to a readjusted size of US$ 1654.2 million by 2028 with a CAGR of 4.6% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, by Type, Freeze-dried Preparation accounting for % of the Eptacog Alfa (rFVIIa) global market in 2021, is projected to value US$  million by 2028, growing at a revised % CAGR from 2022 to 2028. While by Application, Hemophilia was the leading segment, accounting for over  percent market share in 2021, and altered to an  % CAGR throughout this forecast period.

Novo Nordisk is the largest manufacturers of eptacog alfa (rFVIIa) in the world, has a share about 92%. Other players include LFB SA, GENERIUM,Northland-bio, and Northland-bioi, etc. The key players are mainly located in Europe, North America, China, and Japan. In terms of product, freeze-dried preparation is the largest segment, with a share over 52%. And in terms of application, the largest application is hemophilia, with a share over 48%, followed by acquired hemophilia.

Global Eptacog Alfa (rFVIIa) Scope and Market Size
Eptacog Alfa (rFVIIa) market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Eptacog Alfa (rFVIIa) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the Eptacog Alfa (rFVIIa) market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type
    Freeze-dried Preparation
    Freeze-dried Powder

Segment by Application
    Hemophilia
    Acquired Hemophilia
    Factor VII Deficiency
    Glanzmann Thrombasthenia (GT)

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        China Taiwan
        Indonesia
        Thailand
        Malaysia
    Latin America
        Mexico
        Brazil
        Argentina
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

By Company
    Novo Nordisk
    LFB SA
    GENERIUM
    Northland-bio
    CSL
    Shire (Takeda)
    Bayer

 1 Study Coverage
    1.1 Eptacog Alfa (rFVIIa) Product Introduction
    1.2 Global Eptacog Alfa (rFVIIa) Outlook 2017 VS 2022 VS 2028
        1.2.1 Global Eptacog Alfa (rFVIIa) Sales in US$ Million for the Year 2017-2028
        1.2.2 Global Eptacog Alfa (rFVIIa) Sales in Volume for the Year 2017-2028
    1.3 United States Eptacog Alfa (rFVIIa) Outlook 2017 VS 2022 VS 2028
        1.3.1 United States Eptacog Alfa (rFVIIa) Sales in US$ Million for the Year 2017-2028
        1.3.2 United States Eptacog Alfa (rFVIIa) Sales in Volume for the Year 2017-2028
    1.4 Eptacog Alfa (rFVIIa) Market Size, United States VS Global, 2017 VS 2022 VS 2028
        1.4.1 The Market Share of United States Eptacog Alfa (rFVIIa) in Global, 2017 VS 2022 VS 2028
        1.4.2 The Growth Rate of Eptacog Alfa (rFVIIa) Market Size, United States VS Global, 2017 VS 2022 VS 2028
    1.5 Eptacog Alfa (rFVIIa) Market Dynamics
        1.5.1 Eptacog Alfa (rFVIIa) Industry Trends
        1.5.2 Eptacog Alfa (rFVIIa) Market Drivers
        1.5.3 Eptacog Alfa (rFVIIa) Market Challenges
        1.5.4 Eptacog Alfa (rFVIIa) Market Restraints
    1.6 Study Objectives
    1.7 Years Considered

 2 Market by Type
    2.1 Eptacog Alfa (rFVIIa) Market Segment by Type
        2.1.1 Freeze-dried Preparation
        2.1.2 Freeze-dried Powder
    2.2 Global Eptacog Alfa (rFVIIa) Market Size by Type
        2.2.1 Global Eptacog Alfa (rFVIIa) Sales in Value, by Type (2017, 2022 & 2028)
        2.2.2 Global Eptacog Alfa (rFVIIa) Sales in Volume, by Type (2017, 2022 & 2028)
        2.2.3 Global Eptacog Alfa (rFVIIa) Average Selling Price (ASP) by Type (2017, 2022 & 2028)
    2.3 United States Eptacog Alfa (rFVIIa) Market Size by Type
        2.3.1 United States Eptacog Alfa (rFVIIa) Sales in Value, by Type (2017, 2022 & 2028)
        2.3.2 United States Eptacog Alfa (rFVIIa) Sales in Volume, by Type (2017, 2022 & 2028)
        2.3.3 United States Eptacog Alfa (rFVIIa) Average Selling Price (ASP) by Type (2017, 2022 & 2028)

 3 Market by Application
    3.1 Eptacog Alfa (rFVIIa) Market Segment by Application
        3.1.1 Hemophilia
        3.1.2 Acquired Hemophilia
        3.1.3 Factor VII Deficiency
        3.1.4 Glanzmann Thrombasthenia (GT)
    3.2 Global Eptacog Alfa (rFVIIa) Market Size by Application
        3.2.1 Global Eptacog Alfa (rFVIIa) Sales in Value, by Application (2017, 2022 & 2028)
        3.2.2 Global Eptacog Alfa (rFVIIa) Sales in Volume, by Application (2017, 2022 & 2028)
        3.3.3 Global Eptacog Alfa (rFVIIa) Average Selling Price (ASP) by Application (2017, 2022 & 2028)
    3.3 United States Eptacog Alfa (rFVIIa) Market Size by Application
        3.3.1 United States Eptacog Alfa (rFVIIa) Sales in Value, by Application (2017, 2022 & 2028)
        3.3.2 United States Eptacog Alfa (rFVIIa) Sales in Volume, by Application (2017, 2022 & 2028)
        3.3.3 United States Eptacog Alfa (rFVIIa) Average Selling Price (ASP) by Application (2017, 2022 & 2028)

 4 Global Eptacog Alfa (rFVIIa) Competitor Landscape by Company
    4.1 Global Eptacog Alfa (rFVIIa) Market Size by Company
        4.1.1 Top Global Eptacog Alfa (rFVIIa) Manufacturers Ranked by Revenue (2021)
        4.1.2 Global Eptacog Alfa (rFVIIa) Revenue by Manufacturer (2017-2022)
        4.1.3 Global Eptacog Alfa (rFVIIa) Sales by Manufacturer (2017-2022)
        4.1.4 Global Eptacog Alfa (rFVIIa) Price by Manufacturer (2017-2022)
    4.2 Global Eptacog Alfa (rFVIIa) Concentration Ratio (CR)
        4.2.1 Eptacog Alfa (rFVIIa) Market Concentration Ratio (CR) (2017-2022)
        4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Eptacog Alfa (rFVIIa) in 2021
        4.2.3 Global Eptacog Alfa (rFVIIa) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    4.3 Global Eptacog Alfa (rFVIIa) Manufacturing Base Distribution, Product Type
        4.3.1 Global Eptacog Alfa (rFVIIa) Manufacturers, Headquarters and Distribution of Producing Region
        4.3.2 Manufacturers Eptacog Alfa (rFVIIa) Product Type
        4.3.3 Date of International Manufacturers Enter into Eptacog Alfa (rFVIIa) Market
    4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
    4.5 United States Eptacog Alfa (rFVIIa) Market Size by Company
        4.5.1 Top Eptacog Alfa (rFVIIa) Players in United States, Ranked by Revenue (2021)
        4.5.2 United States Eptacog Alfa (rFVIIa) Revenue by Players (2020, 2021 & 2022)
        4.5.3 United States Eptacog Alfa (rFVIIa) Sales by Players (2020, 2021 & 2022)

 5 Global Eptacog Alfa (rFVIIa) Market Size by Region
    5.1 Global Eptacog Alfa (rFVIIa) Market Size by Region: 2017 VS 2022 VS 2028
    5.2 Global Eptacog Alfa (rFVIIa) Market Size in Volume by Region (2017-2028)
        5.2.1 Global Eptacog Alfa (rFVIIa) Sales in Volume by Region: 2017-2022
        5.2.2 Global Eptacog Alfa (rFVIIa) Sales in Volume Forecast by Region (2023-2028)
    5.3 Global Eptacog Alfa (rFVIIa) Market Size in Value by Region (2017-2028)
        5.3.1 Global Eptacog Alfa (rFVIIa) Sales in Value by Region: 2017-2022
        5.3.2 Global Eptacog Alfa (rFVIIa) Sales in Value by Region: 2023-2028

 6 Segment in Region Level & Country Level
    6.1 North America
        6.1.1 North America Eptacog Alfa (rFVIIa) Market Size YoY Growth 2017-2028
        6.1.2 North America Eptacog Alfa (rFVIIa) Market Facts & Figures by Country (2017, 2022 & 2028)
        6.1.3 United States
        6.1.4 Canada
    6.2 Asia-Pacific
        6.2.1 Asia-Pacific Eptacog Alfa (rFVIIa) Market Size YoY Growth 2017-2028
        6.2.2 Asia-Pacific Eptacog Alfa (rFVIIa) Market Facts & Figures by Region (2017, 2022 & 2028)
        6.2.3 China
        6.2.4 Japan
        6.2.5 South Korea
        6.2.6 India
        6.2.7 Australia
        6.2.8 China Taiwan
        6.2.9 Indonesia
        6.2.10 Thailand
        6.2.11 Malaysia
    6.3 Europe
        6.3.1 Europe Eptacog Alfa (rFVIIa) Market Size YoY Growth 2017-2028
        6.3.2 Europe Eptacog Alfa (rFVIIa) Market Facts & Figures by Country (2017, 2022 & 2028)
        6.3.3 Germany
        6.3.4 France
        6.3.5 U.K.
        6.3.6 Italy
        6.3.7 Russia
    6.4 Latin America
        6.4.1 Latin America Eptacog Alfa (rFVIIa) Market Size YoY Growth 2017-2028
        6.4.2 Latin America Eptacog Alfa (rFVIIa) Market Facts & Figures by Country (2017, 2022 & 2028)
        6.4.3 Mexico
        6.4.4 Brazil
        6.4.5 Argentina
    6.5 Middle East and Africa
        6.5.1 Middle East and Africa Eptacog Alfa (rFVIIa) Market Size YoY Growth 2017-2028
        6.5.2 Middle East and Africa Eptacog Alfa (rFVIIa) Market Facts & Figures by Country (2017, 2022 & 2028)
        6.5.3 Turkey
        6.5.4 Saudi Arabia
        6.5.5 UAE

 7 Company Profiles
    7.1 Novo Nordisk
        7.1.1 Novo Nordisk Corporation Information
        7.1.2 Novo Nordisk Description and Business Overview
        7.1.3 Novo Nordisk Eptacog Alfa (rFVIIa) Sales, Revenue and Gross Margin (2017-2022)
        7.1.4 Novo Nordisk Eptacog Alfa (rFVIIa) Products Offered
        7.1.5 Novo Nordisk Recent Development
    7.2 LFB SA
        7.2.1 LFB SA Corporation Information
        7.2.2 LFB SA Description and Business Overview
        7.2.3 LFB SA Eptacog Alfa (rFVIIa) Sales, Revenue and Gross Margin (2017-2022)
        7.2.4 LFB SA Eptacog Alfa (rFVIIa) Products Offered
        7.2.5 LFB SA Recent Development
    7.3 GENERIUM
        7.3.1 GENERIUM Corporation Information
        7.3.2 GENERIUM Description and Business Overview
        7.3.3 GENERIUM Eptacog Alfa (rFVIIa) Sales, Revenue and Gross Margin (2017-2022)
        7.3.4 GENERIUM Eptacog Alfa (rFVIIa) Products Offered
        7.3.5 GENERIUM Recent Development
    7.4 Northland-bio
        7.4.1 Northland-bio Corporation Information
        7.4.2 Northland-bio Description and Business Overview
        7.4.3 Northland-bio Eptacog Alfa (rFVIIa) Sales, Revenue and Gross Margin (2017-2022)
        7.4.4 Northland-bio Eptacog Alfa (rFVIIa) Products Offered
        7.4.5 Northland-bio Recent Development
    7.5 CSL
        7.5.1 CSL Corporation Information
        7.5.2 CSL Description and Business Overview
        7.5.3 CSL Eptacog Alfa (rFVIIa) Sales, Revenue and Gross Margin (2017-2022)
        7.5.4 CSL Eptacog Alfa (rFVIIa) Products Offered
        7.5.5 CSL Recent Development
    7.6 Shire (Takeda)
        7.6.1 Shire (Takeda) Corporation Information
        7.6.2 Shire (Takeda) Description and Business Overview
        7.6.3 Shire (Takeda) Eptacog Alfa (rFVIIa) Sales, Revenue and Gross Margin (2017-2022)
        7.6.4 Shire (Takeda) Eptacog Alfa (rFVIIa) Products Offered
        7.6.5 Shire (Takeda) Recent Development
    7.7 Bayer
        7.7.1 Bayer Corporation Information
        7.7.2 Bayer Description and Business Overview
        7.7.3 Bayer Eptacog Alfa (rFVIIa) Sales, Revenue and Gross Margin (2017-2022)
        7.7.4 Bayer Eptacog Alfa (rFVIIa) Products Offered
        7.7.5 Bayer Recent Development

 8 Industry Chain and Sales Channels Analysis
    8.1 Eptacog Alfa (rFVIIa) Industry Chain Analysis
    8.2 Eptacog Alfa (rFVIIa) Key Raw Materials
        8.2.1 Key Raw Materials
        8.2.2 Eptacog Alfa (rFVIIa) Distributors
    8.3 Eptacog Alfa (rFVIIa) Production Mode & Process
    8.4 Eptacog Alfa (rFVIIa) Sales and Marketing
        8.4.1 Eptacog Alfa (rFVIIa) Sales Channels
        8.4.2 Eptacog Alfa (rFVIIa) Distributors
    8.5 Eptacog Alfa (rFVIIa) Customers

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

List of Tables
    Table 1. Eptacog Alfa (rFVIIa) CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
    Table 2. Eptacog Alfa (rFVIIa) Market Trends
    Table 3. Eptacog Alfa (rFVIIa) Market Drivers
    Table 4. Eptacog Alfa (rFVIIa) Market Challenges
    Table 5. Eptacog Alfa (rFVIIa) Market Restraints
    Table 6. Global Eptacog Alfa (rFVIIa) Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Eptacog Alfa (rFVIIa) Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Eptacog Alfa (rFVIIa) Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Eptacog Alfa (rFVIIa) Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Eptacog Alfa (rFVIIa) Manufacturers in Global Market, Ranking by Revenue (2021)
    Table 11. Global Eptacog Alfa (rFVIIa) Revenue by Manufacturer, (US$ Million), 2017-2022
    Table 12. Global Eptacog Alfa (rFVIIa) Revenue Share by Manufacturer, 2017-2022
    Table 13. Global Eptacog Alfa (rFVIIa) Sales by Manufacturer, (g), 2017-2022
    Table 14. Global Eptacog Alfa (rFVIIa) Sales Share by Manufacturer, 2017-2022
    Table 15. Global Eptacog Alfa (rFVIIa) Price by Manufacturer (2017-2022) & (US$/mg)
    Table 16. Global Eptacog Alfa (rFVIIa) Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 17. Global Eptacog Alfa (rFVIIa) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Eptacog Alfa (rFVIIa) as of 2021)
    Table 18. Top Players of Eptacog Alfa (rFVIIa) in Global Market, Headquarters and Distribution of Producing Region
    Table 19. Manufacturers Eptacog Alfa (rFVIIa) Product Type
    Table 20. Date of International Manufacturers Enter into Eptacog Alfa (rFVIIa) Market
    Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 22. Top Eptacog Alfa (rFVIIa) Players in United States Market, Ranking by Revenue (2021)
    Table 23. United States Eptacog Alfa (rFVIIa) Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 24. United States Eptacog Alfa (rFVIIa) Revenue Share by Players, 2020, 2021 & 2022
    Table 25. United States Eptacog Alfa (rFVIIa) Sales by Players, (g), 2020, 2021 & 2022
    Table 26. United States Eptacog Alfa (rFVIIa) Sales Share by Players, 2020, 2021 & 2022
    Table 27. Global Eptacog Alfa (rFVIIa) Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 28. Global Eptacog Alfa (rFVIIa) Sales in Volume by Region (2017-2022) & (g)
    Table 29. Global Eptacog Alfa (rFVIIa) Sales in Volume Forecast by Region (2023-2028) & (g)
    Table 30. Global Eptacog Alfa (rFVIIa) Sales in Value by Region (2017-2022) & (US$ Million)
    Table 31. Global Eptacog Alfa (rFVIIa) Sales in Value Forecast by Region (2023-2028) & (US$ Million)
    Table 32. North America Eptacog Alfa (rFVIIa) Sales in Volume by Country (2017-2028) & (g)
    Table 33. North America Eptacog Alfa (rFVIIa) Sales in Value by Country (2017-2028) & (US$ Million)
    Table 34. Asia Pacific Eptacog Alfa (rFVIIa) Sales in Volume by Region (2017-2028) & (g)
    Table 35. Asia Pacific Eptacog Alfa (rFVIIa) Sales in Value by Region (2017-2028) & (US$ Million)
    Table 36. Europe Eptacog Alfa (rFVIIa) Sales in Volume by Country (2017-2028) & (g)
    Table 37. Europe Eptacog Alfa (rFVIIa) Sales in Value by Country (2017-2028) & (US$ Million)
    Table 38. Latin America Eptacog Alfa (rFVIIa) Sales in Volume by Country (2017-2028) & (g)
    Table 39. Latin Americaa Eptacog Alfa (rFVIIa) Sales in Value by Country (2017-2028) & (US$ Million)
    Table 40. Middle East and Africa Eptacog Alfa (rFVIIa) Sales in Volume by Country (2017-2028) & (g)
    Table 41. Middle East and Africa Eptacog Alfa (rFVIIa) Sales in Value by Country (2017-2028) & (US$ Million)
    Table 42. Novo Nordisk Corporation Information
    Table 43. Novo Nordisk Description and Business Overview
    Table 44. Novo Nordisk Eptacog Alfa (rFVIIa) Sales (g), Revenue (US$ Million), Price (US$/mg) and Gross Margin (2017-2022)
    Table 45. Novo Nordisk Eptacog Alfa (rFVIIa) Product
    Table 46. Novo Nordisk Recent Development
    Table 47. LFB SA Corporation Information
    Table 48. LFB SA Description and Business Overview
    Table 49. LFB SA Eptacog Alfa (rFVIIa) Sales (g), Revenue (US$ Million), Price (US$/mg) and Gross Margin (2017-2022)
    Table 50. LFB SA Product
    Table 51. LFB SA Recent Development
    Table 52. GENERIUM Corporation Information
    Table 53. GENERIUM Description and Business Overview
    Table 54. GENERIUM Eptacog Alfa (rFVIIa) Sales (g), Revenue (US$ Million), Price (US$/mg) and Gross Margin (2017-2022)
    Table 55. GENERIUM Product
    Table 56. GENERIUM Recent Development
    Table 57. Northland-bio Corporation Information
    Table 58. Northland-bio Description and Business Overview
    Table 59. Northland-bio Eptacog Alfa (rFVIIa) Sales (g), Revenue (US$ Million), Price (US$/mg) and Gross Margin (2017-2022)
    Table 60. Northland-bio Product
    Table 61. Northland-bio Recent Development
    Table 62. CSL Corporation Information
    Table 63. CSL Description and Business Overview
    Table 64. CSL Eptacog Alfa (rFVIIa) Sales (g), Revenue (US$ Million), Price (US$/mg) and Gross Margin (2017-2022)
    Table 65. CSL Product
    Table 66. CSL Recent Development
    Table 67. Shire (Takeda) Corporation Information
    Table 68. Shire (Takeda) Description and Business Overview
    Table 69. Shire (Takeda) Eptacog Alfa (rFVIIa) Sales (g), Revenue (US$ Million), Price (US$/mg) and Gross Margin (2017-2022)
    Table 70. Shire (Takeda) Product
    Table 71. Shire (Takeda) Recent Development
    Table 72. Bayer Corporation Information
    Table 73. Bayer Description and Business Overview
    Table 74. Bayer Eptacog Alfa (rFVIIa) Sales (g), Revenue (US$ Million), Price (US$/mg) and Gross Margin (2017-2022)
    Table 75. Bayer Product
    Table 76. Bayer Recent Development
    Table 77. Key Raw Materials Lists
    Table 78. Raw Materials Key Suppliers Lists
    Table 79. Eptacog Alfa (rFVIIa) Customers List
    Table 80. Eptacog Alfa (rFVIIa) Distributors List
    Table 81. Research Programs/Design for This Report
    Table 82. Key Data Information from Secondary Sources
    Table 83. Key Data Information from Primary Sources
List of Figures
    Figure 1. Eptacog Alfa (rFVIIa) Product Picture
    Figure 2. Global Eptacog Alfa (rFVIIa) Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Eptacog Alfa (rFVIIa) Market Size 2017-2028 (US$ Million)
    Figure 4. Global Eptacog Alfa (rFVIIa) Sales 2017-2028 (g)
    Figure 5. United States Eptacog Alfa (rFVIIa) Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 6. United States Eptacog Alfa (rFVIIa) Market Size 2017-2028 (US$ Million)
    Figure 7. United States Eptacog Alfa (rFVIIa) Sales 2017-2028 (g)
    Figure 8. United States Eptacog Alfa (rFVIIa) Market Share in Global, in Value (US$ Million) 2017-2028
    Figure 9. United States Eptacog Alfa (rFVIIa) Market Share in Global, in Volume (g) 2017-2028
    Figure 10. Eptacog Alfa (rFVIIa) Report Years Considered
    Figure 11. Product Picture of Freeze-dried Preparation
    Figure 12. Product Picture of Freeze-dried Powder
    Figure 13. Global Eptacog Alfa (rFVIIa) Market Share by Type in 2022 & 2028
    Figure 14. Global Eptacog Alfa (rFVIIa) Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 15. Global Eptacog Alfa (rFVIIa) Sales Market Share in Value by Type (2017-2028)
    Figure 16. Global Eptacog Alfa (rFVIIa) Sales by Type (2017-2028) & (g)
    Figure 17. Global Eptacog Alfa (rFVIIa) Sales Market Share in Volume by Type (2017-2028)
    Figure 18. Global Eptacog Alfa (rFVIIa) Price by Type (2017-2028) & (US$/mg)
    Figure 19. United States Eptacog Alfa (rFVIIa) Market Share by Type in 2022 & 2028
    Figure 20. United States Eptacog Alfa (rFVIIa) Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 21. United States Eptacog Alfa (rFVIIa) Sales Market Share in Value by Type (2017-2028)
    Figure 22. United States Eptacog Alfa (rFVIIa) Sales by Type (2017-2028) & (g)
    Figure 23. United States Eptacog Alfa (rFVIIa) Sales Market Share in Volume by Type (2017-2028)
    Figure 24. United States Eptacog Alfa (rFVIIa) Price by Type (2017-2028) & (US$/mg)
    Figure 25. Product Picture of Hemophilia
    Figure 26. Product Picture of Acquired Hemophilia
    Figure 27. Product Picture of Factor VII Deficiency
    Figure 28. Product Picture of Glanzmann Thrombasthenia (GT)
    Figure 29. Global Eptacog Alfa (rFVIIa) Market Share by Application in 2022 & 2028
    Figure 30. Global Eptacog Alfa (rFVIIa) Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 31. Global Eptacog Alfa (rFVIIa) Sales Market Share in Value by Application (2017-2028)
    Figure 32. Global Eptacog Alfa (rFVIIa) Sales by Application (2017-2028) & (g)
    Figure 33. Global Eptacog Alfa (rFVIIa) Sales Market Share in Volume by Application (2017-2028)
    Figure 34. Global Eptacog Alfa (rFVIIa) Price by Application (2017-2028) & (US$/mg)
    Figure 35. United States Eptacog Alfa (rFVIIa) Market Share by Application in 2022 & 2028
    Figure 36. United States Eptacog Alfa (rFVIIa) Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 37. United States Eptacog Alfa (rFVIIa) Sales Market Share in Value by Application (2017-2028)
    Figure 38. United States Eptacog Alfa (rFVIIa) Sales by Application (2017-2028) & (g)
    Figure 39. United States Eptacog Alfa (rFVIIa) Sales Market Share in Volume by Application (2017-2028)
    Figure 40. United States Eptacog Alfa (rFVIIa) Price by Application (2017-2028) & (US$/mg)
    Figure 41. North America Eptacog Alfa (rFVIIa) Sales in Volume Growth Rate 2017-2028 (g)
    Figure 42. North America Eptacog Alfa (rFVIIa) Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 43. United States Eptacog Alfa (rFVIIa) Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 44. Canada Eptacog Alfa (rFVIIa) Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 45. Europe Eptacog Alfa (rFVIIa) Sales in Volume Growth Rate 2017-2028 (g)
    Figure 46. Europe Eptacog Alfa (rFVIIa) Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 47. Germany Eptacog Alfa (rFVIIa) Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 48. France Eptacog Alfa (rFVIIa) Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 49. U.K. Eptacog Alfa (rFVIIa) Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Italy Eptacog Alfa (rFVIIa) Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 51. Russia Eptacog Alfa (rFVIIa) Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 52. Asia-Pacific Eptacog Alfa (rFVIIa) Sales in Volume Growth Rate 2017-2028 (g)
    Figure 53. Asia-Pacific Eptacog Alfa (rFVIIa) Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 54. China Eptacog Alfa (rFVIIa) Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 55. Japan Eptacog Alfa (rFVIIa) Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 56. South Korea Eptacog Alfa (rFVIIa) Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 57. India Eptacog Alfa (rFVIIa) Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 58. Australia Eptacog Alfa (rFVIIa) Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 59. China Taiwan Eptacog Alfa (rFVIIa) Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 60. Indonesia Eptacog Alfa (rFVIIa) Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 61. Thailand Eptacog Alfa (rFVIIa) Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 62. Malaysia Eptacog Alfa (rFVIIa) Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 63. Latin America Eptacog Alfa (rFVIIa) Sales in Volume Growth Rate 2017-2028 (g)
    Figure 64. Latin America Eptacog Alfa (rFVIIa) Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 65. Mexico Eptacog Alfa (rFVIIa) Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 66. Brazil Eptacog Alfa (rFVIIa) Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 67. Argentina Eptacog Alfa (rFVIIa) Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 68. Middle East & Africa Eptacog Alfa (rFVIIa) Sales in Volume Growth Rate 2017-2028 (g)
    Figure 69. Middle East & Africa Eptacog Alfa (rFVIIa) Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 70. Turkey Eptacog Alfa (rFVIIa) Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 71. Saudi Arabia Eptacog Alfa (rFVIIa) Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 72. UAE Eptacog Alfa (rFVIIa) Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 73. Eptacog Alfa (rFVIIa) Value Chain
    Figure 74. Eptacog Alfa (rFVIIa) Production Process
    Figure 75. Channels of Distribution
    Figure 76. Distributors Profiles
    Figure 77. Bottom-up and Top-down Approaches for This Report
    Figure 78. Data Triangulation
    Figure 79. Key Executives Interviewed

Recombinant human coagulation factor VIIa is a drug from Novo Nordisk for bleeding episodes and prevention of bleeding during surgical procedures or invasive procedures in the following patient groups:
1. Inhibitors of coagulation factor VIII or IX 5BU in congenital hemophilia patients; 2. Congenital hemophilia patients who are expected to have a high memory response to injection of coagulation factor VIII or coagulation factor IX; 3. Acquired blood 4. Patients with congenital FVII deficiency; 5. Patients with thrombocytopenia who have GP IIb-IIIa and/or HLA antibodies and past or present ineffective or poor platelet transfusions.

Market Analysis and Insights: Global and United States Eptacog Alfa (rFVIIa) Market
This report focuses on global and United States Eptacog Alfa (rFVIIa) market, also covers the segmentation data of other regions in regional level and county level.

Due to the COVID-19 pandemic, the global Eptacog Alfa (rFVIIa) market size is estimated to be worth US$ 1263 million in 2022 and is forecast to a readjusted size of US$ 1654.2 million by 2028 with a CAGR of 4.6% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, by Type, Freeze-dried Preparation accounting for % of the Eptacog Alfa (rFVIIa) global market in 2021, is projected to value US$  million by 2028, growing at a revised % CAGR from 2022 to 2028. While by Application, Hemophilia was the leading segment, accounting for over  percent market share in 2021, and altered to an  % CAGR throughout this forecast period.

Novo Nordisk is the largest manufacturers of eptacog alfa (rFVIIa) in the world, has a share about 92%. Other players include LFB SA, GENERIUM,Northland-bio, and Northland-bioi, etc. The key players are mainly located in Europe, North America, China, and Japan. In terms of product, freeze-dried preparation is the largest segment, with a share over 52%. And in terms of application, the largest application is hemophilia, with a share over 48%, followed by acquired hemophilia.

Global Eptacog Alfa (rFVIIa) Scope and Market Size
Eptacog Alfa (rFVIIa) market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Eptacog Alfa (rFVIIa) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the Eptacog Alfa (rFVIIa) market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type
    Freeze-dried Preparation
    Freeze-dried Powder

Segment by Application
    Hemophilia
    Acquired Hemophilia
    Factor VII Deficiency
    Glanzmann Thrombasthenia (GT)

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        China Taiwan
        Indonesia
        Thailand
        Malaysia
    Latin America
        Mexico
        Brazil
        Argentina
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

By Company
    Novo Nordisk
    LFB SA
    GENERIUM
    Northland-bio
    CSL
    Shire (Takeda)
    Bayer